Advanced pulmonary drug delivery formulations for the treatment of cystic fibrosis

Akshay Parihar; Bhupendra G Prajapati; Himanshu Paliwal; Maheka Shukla; Dignesh Khunt; Sumedh Devrao Bahadure; Sathish Dyawanapelly; Vijayabhaskarreddy Junnuthula

doi:10.1016/j.drudis.2023.103729

Advanced pulmonary drug delivery formulations for the treatment of cystic fibrosis

Drug Discov Today. 2023 Oct;28(10):103729. doi: 10.1016/j.drudis.2023.103729. Epub 2023 Jul 31.

Authors

Akshay Parihar¹, Bhupendra G Prajapati², Himanshu Paliwal³, Maheka Shukla⁴, Dignesh Khunt⁵, Sumedh Devrao Bahadure⁶, Sathish Dyawanapelly⁷, Vijayabhaskarreddy Junnuthula⁸

Affiliations

¹ Faculty of Pharmaceutical Sciences, The ICFAI University, Baddi, Himachal Pradesh, India.
² Shree S.K. Patel College of Pharmaceutical Education and Research, Ganpat University, Mehsana, Gujarat, India. Electronic address: [email protected].
³ Department of Pharmaceutical Technology, Prince of Songkla University, Hat Yai, Songkhla, Thailand.
⁴ Shree S.K. Patel College of Pharmaceutical Education and Research, Ganpat University, Mehsana, Gujarat, India.
⁵ Graduate School of Pharmacy, Gujarat Technological University, Gujarat, India.
⁶ Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research, Guwahati, India.
⁷ Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, Mumbai, India. Electronic address: [email protected].
⁸ Drug Research Program, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5 E, Helsinki, Finland. Electronic address: [email protected].

PMID: 37532219
DOI: 10.1016/j.drudis.2023.103729

Abstract

Cystic fibrosis (CF), a fatal genetic condition, causes thick, sticky mucus. It also causes pancreatic dysfunction, bacterial infection, and increased salt loss. Currently available treatments can improve the patient's quality of life. Drug delivery aided by nanotechnology has been explored to alter the pharmacokinetics and toxicity of drugs. In this short review, we aim to summarize various conventional formulations and highlight advanced formulations delivered via the pulmonary route for the treatment of CF. There is considerable interest in advanced drug delivery formulations addressing the various challenges posed by CF. Despite their potential to be translated for clinical use, we anticipate that a significant amount of effort may still be required for translation to the clinic.

Keywords: CFTR mutations; cystic fibrosis; drug delivery; nanoformulations; pulmonary route.

Publication types

Review